Determinants of adiponectin levels in patients with chronic systolic heart failure.
Adiponectin, an adipocytokine, is secreted by adipocytes and mediates antihypertrophic and anti-inflammatory effects in the heart. Plasma concentrations of adiponectin are decreased in the presence of obesity, insulin resistance, and obesity-associated conditions such as hypertension and coronary heart disease. However, a paradoxical increase in adiponectin levels is observed in human systolic heart failure (HF). We sought to investigate the determinants of adiponectin levels in patients with chronic systolic HF. Total adiponectin levels were measured in 99 patients with stable HF and a left ventricular (LV) ejection fraction of <40%. The determinants of adiponectin levels on univariate analysis were included in a multivariate linear regression model. At baseline, 62% of the patients were black, 63% were men, the mean age was 60 + or - 13 years, the LV ejection fraction was 21 + or - 9%, and the body mass index was 30.6 + or - 6.7 kg/m(2). The mean adiponectin level was 15.8 + or - 15 microg/ml. Beta-Blocker use, body mass index, and blood urea nitrogen were significant determinants of adiponectin level on multivariate analysis. The LV mass, structure, and LV ejection fraction were not related to adiponectin levels on multivariate analysis. The effect of beta-blocker therapy was most marked in nonobese patients with a body mass index <30 kg/m(2). In conclusion, in patients with chronic systolic HF, beta-blocker therapy correlated with lower adiponectin levels, especially in nonobese patients. This relation should be taken into account when studying the complex role of adiponectin in patients with chronic systolic HF.
Biolo
Andreia
A
Division of Cardiology, Hospital de Clínicas de Porto Alegre, Federal University of Rio Grande do Sul, Porto Alegre, Brazil.
Shibata
Rei
R
Ouchi
Noriyuki
N
Kihara
Shinji
S
Sonoda
Mina
M
Walsh
Kenneth
K
Sam
Flora
F
D052242:Adiponectin / Q000097:blood*; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D015415:Biomarkers / Q000097:blood*; D018450:Disease Progression; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005500:Follow-Up Studies; D054143:Heart Failure, Systolic / Q000097:blood* / Q000188:drug therapy / Q000503:physiopathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D010045:Outpatients; D011379:Prognosis; D012189:Retrospective Studies; D012720:Severity of Illness Index; D013318:Stroke Volume; D016277:Ventricular Function, Left / Q000502:physiology
D052242:Adiponectin; D000319:Adrenergic beta-Antagonists; D015415:Biomarkers
Biochem Biophys Res Commun. 1999 Apr 2;257(1):79-83
10092513
Int J Cardiol. 2008 Apr 10;125(2):216-9
18234365
Circulation. 2005 Sep 20;112(12):1756-62
16157772
Circ J. 2009 Jun;73(6):1067-73
19367012
Clin Endocrinol (Oxf). 2003 Jan;58(1):22-9
12519408
Am J Physiol Endocrinol Metab. 2007 Jul;293(1):E83-90
17356008
J Card Fail. 2003 Aug;9(4):333-44
13680555
J Biol Chem. 1995 Nov 10;270(45):26746-9
7592907
J Am Soc Nephrol. 2006 Sep;17(9):2599-606
16885405
Arterioscler Thromb Vasc Biol. 2000 Jun;20(6):1595-9
10845877
Nat Med. 2004 Dec;10(12):1384-9
15558058
J Clin Endocrinol Metab. 2005 Jun;90(6):3665-72
15769985
Cytokine. 2006 May;34(3-4):219-23
16822679
Hypertension. 2004 Jun;43(6):1318-23
15123570
Clin Sci (Lond). 2010 Feb;118(4):281-9
19656085
Circulation. 2003 Feb 11;107(5):671-4
12578865
Obes Res. 2005 Jan;13(1):179-85
15761178
Biochem J. 2008 Dec 1;416(2):161-77
18783346
J Am Coll Cardiol. 2009 Jun 2;53(22):2070-7
19477358
Eur Heart J. 2008 Mar;29(5):649-57
18263867
Int J Cardiol. 2009 Feb 20;132(2):221-6
18192035
Eur Heart J. 2008 May;29(9):1168-80
18390538
Arterioscler Thromb Vasc Biol. 2003 Jan 1;23(1):85-9
12524229
Clin Endocrinol (Oxf). 2004 Sep;61(3):332-8
15355449
Kidney Int Suppl. 2003 May;(84):S98-102
12694320
Eur Heart J. 2007 Jul;28(14):1723-30
17507366
Circ Heart Fail. 2008 Nov;1(4):249-57
19808299
JAMA. 2009 Apr 8;301(14):1451-9
19351942
Circ J. 2006 Dec;70(12):1557-62
17127799
Heart. 2006 Oct;92(10):1420-4
16621874